Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 4/20 | 0.53 |
| ▸ | CTSS | P25774 | 1/20 | 0.51 |
| ▸ | CTSK | P43235 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | TACR1 | P25103 | 1/20 | 0.47 |
| ▸ | CTSG | P08311 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3700091 | 1.00 | CTSL (0.53) | CTSLCTSSCTSKGAARAB9A | |
| SCHEMBL7615303 | 0.92 | ACE (0.56) | CTSLCTSSCTSKPSMB5TACR1 | |
| SCHEMBL3696924 | 0.92 | ACE (0.56) | CTSLCTSSCTSKPSMB5TACR1 | |
| SCHEMBL3692412 | 0.90 | RAB9A (0.48) | CTSLGAARAB9ACTSG | |
| SCHEMBL7610226 | 0.90 | RAB9A (0.48) | CTSLGAARAB9ACTSG | |
| SCHEMBL7617954 | 0.88 | PSMB5 (0.50) | CTSLPSMB5TACR1 | |
| SCHEMBL3701701 | 0.88 | PSMB5 (0.50) | CTSLPSMB5TACR1 | |
| SCHEMBL7620073 | 0.86 | CTSS (0.57) | CTSLCTSSCTSK | |
| SCHEMBL3699589 | 0.86 | CTSS (0.57) | CTSLCTSSCTSK | |
| SCHEMBL5020122 | 0.84 | KMT2A (0.45) | RAB9AL3MBTL1CTSG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140121202-A1 | S-t-BUTYL PROTECTED CYSTEINE DI-PEPTIDE ANALOGS AND RELATED COMPOUNDS | PROMENTIS PHARMACEUTICALS, INC. (US) | 2014-05-01 | — | — | US | disclosed |
| US-8624052-B2 | S-t-butyl protected cysteine di-peptide analogs and related compounds | PROMENTIS PHARMACEUTICALS, INC. (US) | 2014-01-07 | — | — | US | disclosed |
| WO-2012065102-A2 | S-T-BUTYL PROTECTED CYSTEINE DI-PEPTIDE ANALOGS AND RELATED COMPOUNDS | PROMENTIS PHARMACEUTICALS, INC. (US) | 2012-05-18 | — | — | WO | disclosed |
| US-20120122792-A1 | S-t-BUTYL PROTECTED CYSTEINE DI-PEPTIDE ANALOGS AND RELATED COMPOUNDS | PROMENTIS PHARMACEUTICALS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140121202-A1 | S-t-BUTYL PROTECTED CYSTEINE DI-PEPTIDE ANALOGS AND RELATED COMPOUNDS | CSTB, IAPP, VIP | CTSL 112/4885CTSS 115/4885CTSK 398/4885 |
| US-20120122792-A1 | S-t-BUTYL PROTECTED CYSTEINE DI-PEPTIDE ANALOGS AND RELATED COMPOUNDS | CSTB, IAPP, VIP | CTSL 112/4885CTSS 115/4885CTSK 398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.